Men diagnosed at this hospital trust can access the following services:

• Diagnostic Facilities:
• Multiparametric MRI
• Transperineal biopsy under local anaesthetic
• Transperineal biopsy under general anaesthetic
• Choline PET
• PSMA (prostate-specific membrane antigen) PET scan
• Isotope bone scan
• One-stop diagnostic clinic

• Treatment Facilities:
• Chemotherapy

• Support Service Facilities:
• Clinical Nurse Specialist (CNS) in all clinics
• Prostate cancer-specific CNSs
• Advanced PCa CNS
• Urology CNS
• Sexual function services
• Specialist continence services
• Psychological counselling

For Wales, this data completeness relates to patients diagnosed between April 2022 and March 2023.
For England, this data completeness relates to patients diagnosed in 2021. This is the data completeness of the National Cancer Registration Dataset (NCRD). For data completeness of the Rapid Cancer Registration Dataset (RCRD), please refer to the NPCA quarterly reports.

	Diagnosing Trust	Specialist MDT
No. of Cancer Registry records	288	1269
Performance Status recorded	85%	90%
PSA completed	93%	81%
Gleason Score completed	76%	75%
TNM completed	82%	82%

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

	Specialist MDT	National
No. of men with disease status determined	1190	39897
Percentage of men diagnosed with metastatic disease	16%	17%

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

	Specialist MDT	National
No. of men diagnosed with low-risk localised disease	66	4684
Percentage of men with low-risk localised disease receiving radical treatment	8%	8%
No. of men diagnosed with locally advanced disease	524	15410
Percentage of men diagnosed with locally advanced disease receiving radical treatment	61%	68%